Production (Stage)
Lexeo Therapeutics, Inc.
LXEO
$3.88
$0.6118.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.97% | 12.09% | -38.85% | 2.05% | -52.83% |
| Total Depreciation and Amortization | -3.84% | 2.36% | 2.62% | 4.20% | -2.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.46% | -8.07% | 33.17% | 22.09% | 119.49% |
| Change in Net Operating Assets | 205.04% | -186.77% | 427.30% | -156.29% | 397.77% |
| Cash from Operations | 23.34% | -59.08% | 11.64% | -35.55% | -6.34% |
| Capital Expenditure | -- | 100.00% | 61.03% | -15.14% | -153.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 116.67% | -- | 100.00% | 37.50% | -- |
| Cash from Investing | 116.67% | -112,650.60% | 61.93% | -12.95% | -164.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -37.07% | -4.50% | -50.00% | 32.11% | -3.81% |
| Issuance of Common Stock | -97.31% | 16,082.05% | -89.68% | -99.57% | -11.46% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 111.34% | -34.72% | -124.74% | -99.67% | -11.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.00% | -579.28% | 10.55% | -127.28% | -14.44% |